Trends in pediatric lymphoma incidence by global region, age and sex from 1988-2012

Chun, Gabriel Yong Chul; Sample, Jeannette; Hubbard, Aubrey K.; Spector, Logan G.; Williams, Lindsay A.

doi:10.1016/j.canep.2021.101965

Cited by 9 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An annual percent increase of 1% has been documented for the decade 2000-2019 in NHL incidence, and this trend is confirmed by our data [11]. Incidence rates of NHL in Southern Europe seem to be higher than in other regions of the world, especially among adolescents, and with an increasing rate, especially for BL [12]. Nevertheless, five-year overall survival has climbed from 70% in the early 1990 s to nearly 90% in many developed countries, even by eliminating radiotherapy and chemotherapy alone in most protocols [13].…”

Section: Discussionsupporting

confidence: 88%

B–NHL Cases in a Tertiary Pediatric Hematology—Oncology Department: A 20-Year Retrospective Cohort Study

Kyriakidis,

Pelagiadis,

Stratigaki

et al. 2024

Life

View full text Add to dashboard Cite

Non-Hodgkin lymphoma (NHL) is among the five most common pediatric cancer diagnoses in children and adolescents and consists of a heterogeneous group of lymphoid tissue malignancies –with B-cell-derived NHL accounting for nearly 80% of cases. Novel and high-throughput diagnostic tools have significantly increased our understanding of B-NHL biology and molecular pathogenesis, leading to new NHL classifications and treatment options. This retrospective cohort study investigated 17 cases of both mature B-cell NHL (Burkitt lymphoma or BL; Diffuse large B-cell lymphoma or DLBCL; Primary mediastinal large B-cell lymphoma or PMBCL; Follicular lymphoma or FL) and immature B-cell progenitor NHL (B-lymphoblastic lymphoma or BLL) that were treated in a tertiary Pediatric Hematology-Oncology Department during the last 20 years. Modern NHL protocols for children, adolescents, and young adults, along with the addition of rituximab, are safe and efficient (100% overall survival; one relapse). Elevated ESR was more prevalent than elevated LDH. Analyses have focused on immune reconstitution (grade ≥3 infections, lymphocyte and immunoglobulin levels recovery) and body-mass-index changes post-treatment, late effects (in 53% of patients), and the presence of histology markers BCL2, BCL6, CD30, cMYC, and Ki-67%. One patient was diagnosed with a second malignant neoplasm (papillary thyroid cancer).

show abstract

Section: Discussionsupporting

confidence: 88%

B–NHL Cases in a Tertiary Pediatric Hematology—Oncology Department: A 20-Year Retrospective Cohort Study

Kyriakidis,

Pelagiadis,

Stratigaki

et al. 2024

Life

View full text Add to dashboard Cite

show abstract

“…While low-grade, clinically indolent lymphomas are predominant in adults, pediatric cases are primarily characterized by high-grade lymphoma subtypes with aggressive behavior. 2 The extranodal presentation of NHL in the child-adolescent population, in contrast to that in adults, is more common and often involves sites such as the mediastinum, abdomen, headneck region, bone marrow, or central nervous system, with symptoms and signs specific of the anatomic site involved. 3 Symptoms often develop rapidly, over a period of 1-3 weeks (see Table 1 for signs and symptoms).…”

Section: Discussionmentioning

confidence: 99%

“…NHL represents a heterogeneous group of malignant neoplasms of lymph node tissue derived from the progenitors or mature B‐lymphocyte cells or, less frequently, T‐ lymphocyte cells. While low‐grade, clinically indolent lymphomas are predominant in adults, pediatric cases are primarily characterized by high‐grade lymphoma subtypes with aggressive behavior 2 . The extranodal presentation of NHL in the child‐adolescent population, in contrast to that in adults, is more common and often involves sites such as the mediastinum, abdomen, head–neck region, bone marrow, or central nervous system, with symptoms and signs specific of the anatomic site involved 3 .…”

Section: Discussionmentioning

confidence: 99%

Pediatric non‐Hodgkin lymphoma as a rare cause of spinal cord injury: When lymphoma hides in the canal

Zama,

Candela,

Pagano

et al. 2024

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageSpinal cord compression from non‐Hodgkin lymphoma (NHL) should be considered as a potential diagnosis in cases of acute signs of myelopathy in pediatric patients.AbstractSpinal cord compression in pediatric non‐Hodgkin lymphoma (NHL) is a rare presentation with potential diagnostic challenges. We report on two pediatric patients with NHL who exhibited myelopathy signs as initial presentation. Considering NHL as a differential diagnosis in pediatric patients presenting with spinal cord compression is crucial for optimizing the outcome of these patients.

show abstract

“…Lymphatic tissue, bone marrow, or extranodal sites may be involved in lymphoma, with extranodal sites being more common among NHL patients. Examples of extranodal sites include Waldeyer's ring, salivary glands, orbit, paranasal sinuses, thyroid glands, larynx, and skin [1][2][3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

STAT3 Expression and Its Correlation with PD‐L1 Expression in Non‐Hodgkin’s Lymphoma and Hodgkin’s Lymphoma at Dr. Saiful Anwar Regional Public Hospital in Malang, Indonesian Population

Hambalie,

Norahmawati,

Endharti

et al. 2024

Advances in Hematology

View full text Add to dashboard Cite

Background. Lymphomas are malignant lymphocyte neoplasms that globally account for 10% of cancers in individuals aged <20 years. Malignant lymphomas are divided into Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). Despite the availability of many therapeutic modalities for lymphoma, such as Brentuximab vedotin, Nivolumab, and Pembrolizumab, it is still necessary to identify appropriate strategies with minimal side effects. Immunotherapy is a promising approach, exemplified by targeting JAK/STAT3 signaling, which can inhibit tumor growth and enhance antitumor immune responses. Hence, STAT3 (signal transducer and activator of transcription 3) is a promising therapeutic target. PD-L1 (programmed death-ligand 1), an immune checkpoint molecule, is used as a frontline treatment for various cancers. This study aims to determine STAT3 expression and its correlation with PD-L1 expression in NHL and HL to serve as a basis for further research on anti-STAT3 and its combination with other therapy targets. Methods. Samples were obtained from paraffin blocks of patients with confirmed diagnoses of NHL and HL, and then immunohistochemical staining was carried out with PD-L1 and STAT3 antibodies. The collected data were then analyzed using SPSS. Results. Among the 10 HL patients, no patients (0%) expressed STAT3, while nine patients (90%) expressed PD-L1. Among the 10 NHL patients, 1 patient (10%) expressed STAT3, while six patients (60%) expressed PD-L1. There were no significant differences in STAT3 expression and PD-L1 expression between HL patients and NHL patients. There was no correlation between STAT3 and PD-L1 expression in HL and NHL because almost all STAT3 expressions were negative. Conclusion. Although this study revealed no differences between STAT3 and PD-L1 expression in HL and NHL and no significant correlation between STAT3 and PD-L1 expression in HL and NHL, this may serve as the basis for understanding the role of STAT3 and PD-L1 in the regulation of HL and NHL, which may be useful for further research targeting STAT3 and PD-L1 immunotherapy in HL and NHL.

show abstract

Trends in pediatric lymphoma incidence by global region, age and sex from 1988-2012

Cited by 9 publications

References 38 publications

B–NHL Cases in a Tertiary Pediatric Hematology—Oncology Department: A 20-Year Retrospective Cohort Study

B–NHL Cases in a Tertiary Pediatric Hematology—Oncology Department: A 20-Year Retrospective Cohort Study

Pediatric non‐Hodgkin lymphoma as a rare cause of spinal cord injury: When lymphoma hides in the canal

STAT3 Expression and Its Correlation with PD‐L1 Expression in Non‐Hodgkin’s Lymphoma and Hodgkin’s Lymphoma at Dr. Saiful Anwar Regional Public Hospital in Malang, Indonesian Population

Contact Info

Product

Resources

About